Rocket Pharmaceuticals announces clearance of IND for RP-L201 gene therapy for LAD-I
Rocket Pharmaceuticals announces clearance of the Company’s Investigational New Drug application by the FDA for RP-L201. RP-L201 is the Company’s lentiviral vector-based gene therapy for the treatment of severe Leukocyte Adhesion Deficiency-I. November 19, 2018